July 2024 in “Age and Ageing” Men taking dutasteride may have a higher risk of age-related macular degeneration.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” Finasteride and dutasteride now have stronger warnings for psychiatric and sexual side effects.
29 citations
,
April 2019 in “BMJ. British medical journal” Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
September 2004 in “Urology” Dutasteride may help prevent prostate cancer, but more research is needed.
April 2016 in “The Journal of Sexual Medicine”
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride and dutasteride effectively treat hair loss, with dutasteride showing slightly better results.
June 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Finasteride and dutasteride effectively treat hair loss, with dutasteride showing slightly better results.
64 citations
,
June 2009 in “Journal of The American Academy of Dermatology” Oral dutasteride can potentially treat frontal fibrosing alopecia in postmenopausal women, with some patients showing disease arrest and hair regrowth.
195 citations
,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
41 citations
,
February 2021 in “Cureus” Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.
August 2024 in “JEADV Clinical Practice” Mesotherapy with dutasteride improves hair growth and reduces symptoms in frontal fibrosing alopecia.
8 citations
,
January 2011 in “Korean Journal of Andrology” The doxazosin plus tamsulosin combination improved symptoms effectively with fewer side effects.
October 2006 in “Urology” The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
46 citations
,
March 2001 in “Journal of endocrinological investigation” 5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.
1 citations
,
August 2018 in “Journal of The American Academy of Dermatology” Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.
December 2025 in “Journal of Cosmetic Dermatology” Intralesional dutasteride improves hair growth in androgenic alopecia with minimal side effects.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
June 2025 in “Experimental and Сlinical Urology” Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
June 2010 in “Urology times” Finasteride causes fewer sexual side effects than dutasteride in men with BPH.
15 citations
,
January 2018 in “Acta dermato-venereologica” Finasteride and dutasteride increase sexual dysfunction risk by 1.57 times in male hair loss treatment.
May 2026 in “Reactions Weekly” Finasteride and dutasteride may increase the risk of suicide and sexual dysfunction.
1 citations
,
January 2021 in “Acta Cirurgica Brasileira” Dutasteride and finasteride cause kidney damage, with dutasteride being more harmful.
November 2013 in “Journal of clinical & experimental dermatology research” Dutasteride can help treat hair loss in both men and women.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Oral dutasteride is a recommended first treatment for frontal fibrosing alopecia.
December 2010 in “Actas Urológicas Españolas” Taking dutasteride for one month before prostate surgery can reduce bleeding.